QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hudson, J. Q Search for Related Content PubMed PubMed Citation Articles by Hudson, J. Q

NEPHROLOGY

Secondary Hyperparathyroidism in Chronic Kidney Disease: Focus on Clinical Consequences and Vitamin D Therapies

¹ Associate Professor, Department of Clinical Pharmacy; Assistant Professor, Department of Medicine (Nephrology), The University of Tennessee, Memphis, TN

Reprints: Dr. Hudson, Department of Clinical Pharmacy, The University of Tennessee, 26 S. Dunlap St., Ste. 210, Memphis, TN 38163-0001, fax 901/448-6064, jhudson{at}utmem.edu

OBJECTIVE: To assess vitamin D-based treatment approaches for secondary hyperparathyroidism and its complications.

DATA SOURCES: A literature search was performed using MEDLINE (1990-February 28, 2006). Key words used were chronic kidney disease and vitamin D to identify relevant papers published in English.

STUDY SELECTION AND DATA EXTRACTION: From the database of articles generated, 48 papers were identified. Titles and abstracts were examined to identify those directly related to the objective. Discussion was expanded through the bibliographies of cited articles.

DATA SYNTHESIS: The increasing prevalence of chronic kidney disease (CKD) in the US indicates an urgent need for treatment strategies to delay or prevent disease progression. Abnormalities in phosphorus and calcium homeostasis, vitamin D levels, and the subsequent development of secondary hyperparathyroidism (SHPT) are secondary complications of CKD associated with increased morbidity and mortality. Management options include dietary phosphorus restriction, phosphate binders and/or calcium supplementation, vitamin D supplementation, and calcimimetics. Vitamin D supplementation has received increased attention given the prevalence of vitamin D deficiency in patients with CKD and the beneficial effect of correcting this deficiency.

CONCLUSIONS: Early identification and intervention appropriate to the stage of CKD are likely to improve patient outcomes. Improved knowledge of interactions between vitamin D and vitamin D receptors has led to the development of vitamin D analogs and calcimimetics, which offer benefits in the management of SHPT. Integrating available treatment options into practice to achieve optimal therapeutic goals of SHPT based on the stage of CKD is a significant challenge for pharmacists managing patients with CKD.

Key Words: chronic kidney disease, secondary hyperparathyroidism, vitamin D

Published Online, August 15, 2006. www.theannals.com, DOI 10.1345/aph.1G724

This article has been cited by other articles:

				H. Kumar K. V. S., K. D. Modi, and R. Jha Vitamin D Therapy and Reduced Mortality in Chronic Kidney Disease Arch Intern Med, October 13, 2008; 168(18): 2045 - 2046. [Full Text] [PDF]

				P. Raggi and M. Kleerekoper Contribution of Bone and Mineral Abnormalities to Cardiovascular Disease in Patients with Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 836 - 843. [Abstract] [Full Text] [PDF]

				M. Sneve, N. Emaus, R. M. Joakimsen, and R. Jorde The association between serum parathyroid hormone and bone mineral density, and the impact of smoking: the Tromso Study Eur. J. Endocrinol., March 1, 2008; 158(3): 401 - 409. [Abstract] [Full Text] [PDF]